FyMed has integrated advanced methodologies in personalized medicine that have enabled major breakthroughs in the development of novel and improved drug development strategies.
Wilmington, DE (PRWEB) September 20, 2011
FyMed, Inc., a biopharmaceutical company focused on innovative drug development through sophisticated biomarker discovery methodologies in personalized medicine, today announced strategic and operational expansion plans following the successful completion of major preclinical drug studies utilizing the Company’s proprietary companion diagnostic and prognostic technologies.
“This expansion will enable us to continue to discover and develop novel linked pharmaceutical-biomarker products that will offer the latest advances in personalized medicine,” said Ben Johns, Ph.D., Vice President of Product Development at FyMed, Inc.
FyMed has developed a portfolio of products by opportunistically leveraging proprietary advanced methodologies in pharmacogenomics and proteomics and effectively integrating this with the drug discovery process. These approaches offered significant advantages to the Company in the development of novel and improved targeted products for both expansive and specialized pharmaceutical markets.
“Current personalized medicine based strategies are limited in market size and value due to inherent differences in patient heterogeneity and pharmacodynamics,” said Ben. “Our technologies enable the identification of large homogenous clusters of biomarker profiles and therapeutic response patterns within patient populations, combinatory approaches that have provided us with major breakthroughs in the development of new ‘blockbuster’ strategies.”
FyMed has utilized these methodologies for several drugs in current development. The Company has successfully completed preclinical studies with three major candidates, demonstrating the potential of significant impact in the pain, inflammation, and the infectious disease market. The Company plans to proceed with clinical trials, and is simultaneously conducting several preclinical studies for various indications.
FyMed’s intended expansions include the strategic application of integrative clinical, pharmacogenomic, proteomic, and molecular phenotypic data with the decisive implementation of focused drug-centric models of companion diagnostics and prognostic driven modalities. Implementation of these approaches will enable the Company to sustain innovation, and lead to more effective and safer therapies in favor of product approval.
FyMed, Inc. is a biopharmaceutical company with a growing portfolio of novel and improved pharmaceuticals developed and enhanced through ultra-sensitive next generation targeted companion diagnostics and prognostics. Leading innovations in personalized medicine has enabled FyMed to effectively balance technological innovation with scientific discovery, creating tools that can productively integrate with drug development and capitalize on key market deficiencies. Additional information is available through FyMed Media Relations or at http://www.fymed.com
Safe Harbor Statement
To the extent any statements made in this document contain information that is not historical, this news release contains "forward-looking statements" within the meaning of Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of the words "intends," "plans," "will," "potential," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described herein. These risks and uncertainties may include, without limitation, projected expansions, outcomes of our clinical trials, achievement of our business objectives, and the ability to obtain necessary regulatory approvals. FyMed undertakes no obligation to publicly update forward-looking statements, whether because of new information, future events or otherwise.
# # #